This week Bobbi Conner talks with Dr. Miriam Alexander about advances in lung cancer treatment in recent years. Dr. Alexander ...
Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
Key Highlights: <li /> Global first immuno + anti-vascular bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC.
Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...
The Hearty Soul on MSN2d
High-Sugar Diet Linked to Lung Cancer, Expanding Our Understanding of Diet's ImpactWe all know at this point that high-sugar diets are not good for us. They increase our risk of developing cardiovascular ...
Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.
Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...
Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback